Area of research
Infectious Diseases · Epidemiology
Research interest
Research interests include Tuberculosis, Medicine, Mycobacterium tuberculosis, Pyrazinamide, Bedaquiline, and Microbiology.
The role of cytochrome bc1 inhibitors in future tuberculosis treatment regimens
Dose optimization of TBI-223 for enhanced therapeutic benefit compared to linezolid in antituberculosis regimen
Short oral regimens for pulmonary rifampicin-resistant tuberculosis (TB-PRACTECAL): an open-label, randomised, controlled, phase 2B-3, multi-arm, multicentre, non-inferiority trial
Discovery of natural-product-derived sequanamycins as potent oral anti-tuberculosis agents
Lysyl-tRNA synthetase, a target for urgently needed M. tuberculosis drugs
Combination of Mycobacterium tuberculosis RS Ratio and CFU Improves the Ability of Murine Efficacy Experiments to Distinguish between Drug Treatments
Development of New Tuberculosis Drugs: Translation to Regimen Composition for Drug-Sensitive and Multidrug-Resistant Tuberculosis
Mechanistic Modeling of Mycobacterium tuberculosis Infection in Murine Models for Drug and Vaccine Efficacy Studies
One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis
Dual β-Lactam Combinations Highly Active against Mycobacterium abscessus Complex <i>In Vitro</i>
Advancing Translational Science for Pulmonary Nontuberculous Mycobacterial Infections. A Road Map for Research
Primary Clofazimine and Bedaquiline Resistance among Isolates from Patients with Multidrug-Resistant Tuberculosis
Mutations in <i>pepQ</i> Confer Low-Level Resistance to Bedaquiline and Clofazimine in Mycobacterium tuberculosis
Bedaquiline and Pyrazinamide Treatment Responses Are Affected by Pulmonary Lesion Heterogeneity in <i>Mycobacterium tuberculosis</i> Infected C3HeB/FeJ Mice
Drug Concentration Thresholds Predictive of Therapy Failure and Death in Children With Tuberculosis: Bread Crumb Trails in Random Forests
Targeting DnaN for tuberculosis therapy using novel griselimycins
Presence of multiple lesion types with vastly different microenvironments in C3HeB/FeJ mice following aerosol infection with <i>Mycobacterium tuberculosis</i>
Contribution of Oxazolidinones to the Efficacy of Novel Regimens Containing Bedaquiline and Pretomanid in a Mouse Model of Tuberculosis
Heterogeneous disease progression and treatment response in a C3HeB/FeJ mouse model of tuberculosis
Host-Mediated Bioactivation of Pyrazinamide: Implications for Efficacy, Resistance, and Therapeutic Alternatives
Limited Activity of Clofazimine as a Single Drug in a Mouse Model of Tuberculosis Exhibiting Caseous Necrotic Granulomas
Principles for designing future regimens for multidrug-resistant tuberculosis
Comprehensive analysis of methods used for the evaluation of compounds against Mycobacterium tuberculosis
Sterilizing Activities of Novel Combinations Lacking First- and Second-Line Drugs in a Murine Model of Tuberculosis
Dose-Ranging Comparison of Rifampin and Rifapentine in Two Pathologically Distinct Murine Models of Tuberculosis
Nonsteroidal anti-inflammatory drug sensitizes <i>Mycobacterium tuberculosis</i> to endogenous and exogenous antimicrobials